Health Care Distributors M&A update, 14–28 September 2026
A bi-weekly read on Health Care Distributors covering public market moves, major company catalysts and M&A activity for September 14–28, 2026. Built for operators, acquirers and advisers who need a fast, sourced view of what changed in the sector and what it means for pricing and deal underwriting.
For information only. Not an appraisal or a fairness opinion.
The deeper read: Health Care Distributors Sector Outlook — September 2026
Key figures
- Sector Median Move
- -4.7%
- 8 covered names, close-to-close
- S&P 500 Return
- +0.8%
- same window
- AMRX Share Move
- +19.0%
- Core-tier name, Sep 14–28
- Precedent Deal Multiple
- 11.4x
- 32 recorded transactions, median EV/LTM EBITDA
Read the report
1 / 7 · HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › HEALTH CARE DISTRIBUTORS
Executive summary
Health Care Distributors saw single-company news, not a sector-wide move, set prices this period: 6 of 8 covered names fell for a -4.7% median move against +0.8% for the S&P 500. Amneal Pharmaceuticals, Inc. (AMRX) was the exception, rising +19.0% on an FDA approval and product launch. No new transactions entered the precedent record, which still stands at 32 deals with a median of 11.4x EV/EBITDA. The takeaway: company evidence, not sector drift, should guide the next two weeks of decisions.
Key findings
- Single-company news, not sector-wide moves, set prices for the two-week period.
- One FDA approval lifted Amneal Pharmaceuticals while the rest of the set slipped.
- The M&A precedent record added no new deals and still anchors at 11.4x EV/EBITDA.
- NeuraCap's tiered valuation split, Premium versus Discount, held unchallenged.
What each page shows
The analyst’s walkthrough of the deck, page by page.
- 01BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE
HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › HEALTH CARE DISTRIBUTORS
This is the cover slide identifying the report as a bi-weekly Health Care Distributors industry events and M&A update for September 14–28, 2026.
This bi-weekly update covers Health Care Distributors for the two-week period ending September 28, 2026, tracking what moved, what companies announced and what transacted. We use it to walk you through the sector's public market moves, major catalysts, deal activity and what it means for operators, buyers and advisers.
Everything on this page
BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › HEALTH CARE DISTRIBUTORS Product Launches Move Prices While the Deal Record Holds Still This update covers what moved, what companies announced and what the transaction record showed across Health Care Distributors from September 14–28, 2026. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Health Care Distributors Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1
- 02THE BI-WEEKLY BOTTOM LINE
Single-Company News, Not a Sector-Wide Move, Set Prices This Period
This slide summarizes the two-week period's headline takeaway: single-company news, not a sector-wide move, set prices.
We start with the bottom line: the covered set gave ground broadly, with a median move of -4.7% against a +0.8% gain for the S&P 500 over the same window. Amneal Pharmaceuticals, Inc. (AMRX) was the one exception, rising +19.0% on an FDA approval and product launch. No new transactions entered the precedent record, which still stands at 32 deals with a median of 11.4x EV/EBITDA. So what: this was a period where company-specific evidence, not sector momentum, explains the winners and losers.
Everything on this page
THE BI-WEEKLY BOTTOM LINE Single-Company News, Not a Sector-Wide Move, Set Prices This Period The two-week period in one page · 8 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Health Care Distributors Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 The Set Gave Ground While the Broad Market Edged Up 6 of 8 covered names fell; the median move was -4.7%. The S&P 500 returned +0.8% over the same window. 2 One Approval Carried the Period's Only Large Gain Amneal Pharmaceuticals, Inc. (AMRX), a Core-tier name, rose +19.0%, with its biggest single session at +8.6%. Shares moved in the same window in which the company announced FDA approval and immediate launch of Lanreotide Injection. 3 The Transaction Record Added Nothing New No material sector transactions were announced during the period. The trailing record of 32 precedent transactions still carries a median of 11.4x EV/EBITDA. 4 The Two-Market Split in the Standing View Held NeuraCap's standing sector view puts the median at 10.4x EV/EBITDA on CY2027E, the Premium tier at 12.6x and the Discount tier at 6.8x. Nothing companies announced over the two-week period challenged that split. +19.0% Best mover — AMRX worst: AVAH -11.8% · 2 up / 6 down of 8 covered -4.7% Sector median two-week return vs S&P 500 +0.8%
- 03PUBLIC MARKET MOVERS
One Approval Lifts a Core-Tier Name While the Rest of the Set Slips
This slide details each covered company's price move for the period, highlighting the approval-driven gain against a broader sector decline.
We show close-to-close moves across the covered set for the two weeks, where the sector median came in at -4.7% versus +0.8% for the S&P 500. Amneal Pharmaceuticals, Inc. (AMRX) stood apart with a +19.0% gain, including a single session of +8.6%, following its FDA approval and launch of Lanreotide Injection. The materiality bar for this window was set at +9.2% on a sector-relative basis, underscoring how unusual that move was. So what: one recorded catalyst, not sector sentiment, explains the period's only outsized winner.
Everything on this page
PUBLIC MARKET MOVERS One Approval Lifts a Core-Tier Name While the Rest of the Set Slips Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median -4.7% · S&P 500 +0.8% · materiality bar ±9.2% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Health Care Distributors Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median -4.7% Amneal Pharmaceuticals, Inc. (AMRX) +19.0% Shares moved following the company's announcement of FDA approval and immediate launch of Lanreotide Injection, a long-acting oncology injectable supported by in-house production. An approved product made in-house adds gross profit dollars, not just units through the channel. COMPANY-SPECIFIC Aveanna Healthcare Holdings Inc. (AVAH) -11.8% No notable in-window news was identified that clearly explains the move. Aveanna Healthcare Holdings Inc. (AVAH) fell -11.8%, a wider decline than the set's median move of -4.7%. Core-tier names can give back ground in a period with no fresh company disclosure to point to. UNEXPLAINED
- 04MAJOR NEWS & INDUSTRY CATALYSTS
Companies Spent the Period on Product, Brand and the Boardroom
This slide lists the period's highest-impact company events across product, brand and governance, each linked to its source.
We surface the two-week period's highest-impact events — product approvals, brand moves and boardroom changes — each tied to a filing or article we can point you to. These are the recorded catalysts behind the price moves shown on the prior page, read with calibrated language rather than asserted causation. So what: this is the evidence base clients can check before acting on any single name.
Everything on this page
MAJOR NEWS & INDUSTRY CATALYSTS Companies Spent the Period on Product, Brand and the Boardroom The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Health Care Distributors Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 28 · NEWS · GlobeNewsWire Tilray expands BrewDog's senior marketing, hospitality, category and international leadership Commercial leadership hires show where the company expects to push volume and mix next. Where a company puts its commercial talent is a practical signal about which margin pool it is chasing. Leadership additions on the commercial side usually precede a change in channel emphasis. Sep 25 · NEWS · Business Wire Cencora elects Robert E. Sanchez to its board as a new independent director Cencora, Inc. (COR) is adding senior transport and logistics leadership experience at board level. Distribution economics are increasingly a network design question, not only a sourcing question. Sep 23 · NEWS · Business Wire McKesson schedules its second quarter fiscal 2027 results and investor webcast McKesson Corporation (MCK) sets the calendar for the next hard read on gross profit dollars per unit and generic sourcing penetration from a Premium-tier wholesaler. The set's mix and sourcing questions wait for the large platforms' own reporting dates. Sep 22 · NEWS · GlobeNewsWire Tilray puts fresh investment behind BrewDog with an 'Under New Ownership' brand campaign Tilray Brands, Inc. (TLRY), a Discount-tier name, is spending behind an acquired brand rather than integrating it quietly. The read is that own-brand pull, not distribution alone, is the intended return on that purchase. Owned brands only pay back when someone funds the demand side after close. Sep 18 · NEWS · GlobeNewsWire Amneal wins FDA approval and launches Lanreotide Injection, produced in-house A complex injectable made on the company's own lines expands the margin pool rather than the revenue line. That is the kind of mix shift the sector's earnings quality debate turns on. Complex injectables and cold chain capability are where added margin dollars are being sought. Sep 17 · NEWS · GlobeNewsWire Kamada confirms KedRAB supply is sufficient as the CDC reports rising U.S. rabies exposures Kamada Ltd. (KMDA) says it can meet increased utilisation of one of only two FDA-approved anti-rabies immunoglobulin products in the U.S. Fill rate against contract matters most in products with few approved alternatives.
- 05M&A & STRATEGIC ACTIVITY
No New Transactions: The Standing Record Remains the Reference Set
This slide confirms that no new sector transactions were announced, leaving the standing precedent record as the reference set.
No new transactions were announced in Health Care Distributors during this window, so the standing precedent record remains the reference set: 32 recorded deals at a median of 11.4x EV/LTM EBITDA. We do not re-present prior deals as news; we simply hold the line on what still anchors underwriting. So what: acquirers and advisers should keep pricing conversations anchored to that trailing multiple until a new deal resets it.
Everything on this page
M&A & STRATEGIC ACTIVITY No New Transactions: The Standing Record Remains the Reference Set September 14–28, 2026 · precedent transactions: 32 recorded deals · median 11.4x EV/LTM EBITDA Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Health Care Distributors Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 No Material Transactions Announced No material sector transactions were announced during the period. The trailing record of 32 precedent transactions carries a median of 11.4x EV/EBITDA, and that remains the reference point buyers and sellers are working from. A quiet two-week period is information: buyer appetite, financing conditions and seller expectations all read through a period with no new deals. The precedent transactions alongside still frame what buyers have paid. 32 Recorded precedent transactions the reference set buyers and sellers price against 11.4x Precedent median EV/LTM EBITDA LTM at announcement, where disclosed
- 06WHAT IT MEANS
What a News-Driven Period Changes for Operators, Buyers and Advisers
This slide translates the period's evidence into implications for operators, acquirers and advisers.
For operators, the period's news spoke to margin dollars per unit shipped and specialty and generic sourcing mix, not headlines. For acquirers, the reference set did not move, so underwriting still sits against 32 prior transactions at a median of 11.4x EV/EBITDA. For advisers, the story this period is company-specific — an approval and launch, a supply assurance, a board addition — so the strongest conversations lead with that evidence rather than sector drift. So what: each audience has a distinct, evidence-based action to take from this window.
Everything on this page
WHAT IT MEANS What a News-Driven Period Changes for Operators, Buyers and Advisers The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Health Care Distributors Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / EBITDA (CY2027E) median 10.4x 9 companies in the study 3 valuation tiers Standing thesis: Health Care Distributors Trades as Two Markets: Scaled Wholesalers and Channel-Adjacent Manufacturers FOR OWNERS & OPERATORS Margin Dollars, Not Headlines, Carried the Period Gross profit dollars per unit shipped, specialty mix as a share of the margin pool and generic sourcing penetration are what the period's news spoke to. FOR ACQUIRERS The Reference Set Did Not Move Nothing new entered the precedent record over the two-week period, so underwriting still sits against 32 prior transactions at a median of 11.4x EV/EBITDA. FOR ADVISORS Lead with Company Evidence, Not Sector Drift The period's story is company-specific: an approval and launch, a supply assurance, a board addition, brand reinvestment.
- 07SOURCES & METHODOLOGY
Sources, Methodology and Important Notice
This slide explains the sources, methodology and reliability order behind every figure and claim in the update.
Every figure in this update links back to the record it was taken from, drawn from market prices, SEC filings and consensus estimates through September 28, 2026. We admit sources in a fixed reliability order — SEC filings, press releases, then established outlets — and never draw on video or social platforms. So what: you can trace any number in this deck back to its primary source before you act on it.
Everything on this page
SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Health Care Distributors Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. 1 name below the floor was excluded from movers and statistics for this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T161832Z_529_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: globenewswire.com · businesswire.com
Sources and methodology
This update covers Health Care Distributors over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 8 listed companies whose core business is Health Care Distributors under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Amneal Pharmaceuticals, Inc. (AMRX), Aveanna Healthcare Holdings Inc. (AVAH), Cardinal Health, Inc. (CAH), Cencora, Inc. (COR), Henry Schein, Inc. (HSIC), Kamada Ltd. (KMDA), McKesson Corporation (MCK), Tilray Brands, Inc. (TLRY). 1 name below the floor was excluded from the statistics: GEG.
Window and company universe
This update covers Health Care Distributors over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 8 listed companies whose core business is Health Care Distributors under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Amneal Pharmaceuticals, Inc. (AMRX), Aveanna Healthcare Holdings Inc. (AVAH), Cardinal Health, Inc. (CAH), Cencora, Inc. (COR), Henry Schein, Inc. (HSIC), Kamada Ltd. (KMDA), McKesson Corporation (MCK), Tilray Brands, Inc. (TLRY). 1 name below the floor was excluded from the statistics: GEG.
How the moves and statistics are computed
Each company's period move is the change in closing price from the last close before the window to the last close inside it (close-to-close). The sector median is the median of those moves across the covered names; the index return is computed the same way for the S&P 500 over the same dates. The largest single-day move inside the window is shown for each mover. Movers are the largest gainers and losers by period move; the attribution cards prefer movers whose in-window record explains the move. Movers carry the valuation tier assigned in the standing sector study (the latest NeuraCap sector outlook) where that study rated them.
Events, news and how a move is attributed
Company events are the 8-K filings made inside the window; news items are publisher-sourced headlines for the window, admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron's and peers). Video and social platforms are never used. A move is linked to an event only when the event falls inside the window and only in calibrated language; where nothing in the record explains a move, the update says so rather than speculating. Every event links to its source.
Transactions in the window and the trailing record
Transactions are taken from SEC filings by announcement date; 0 were announced inside the window. The trailing record of 32 recorded transactions provides the reference multiples (EV over last-twelve-month revenue or EBITDA at announcement, as disclosed). A value whose own citation describes something other than the price paid is not shown as the deal value; transactions where the acquirer and the target are the same entity are treated as reorganisations and excluded.
Sources
Prices and index levels are market data through September 28, 2026; filings are the companies' SEC filings on EDGAR; press releases are the companies' own; other news items are from the established outlets named on each card; Treasury yields are published by the U.S. Department of the Treasury. Every figure and every event in the update links to its record.
Interpretation and important notice
'Why it matters', 'why the deal happened' and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, labelled as such. The update is informational: it is not investment advice, not a recommendation to buy or sell any security and not an offer of any kind.
Sources linked in the report
- +19.0% (globenewswire.com)
- -11.8% (zacks.com)
- Tilray expands BrewDog's senior marketing, hospitality, category and (globenewswire.com)
- Cencora elects Robert E. Sanchez to its board as a new independent (businesswire.com)
- McKesson schedules its second quarter fiscal 2027 results and investor (businesswire.com)
- Tilray puts fresh investment behind BrewDog with an 'Under New Ownership' (globenewswire.com)
- Kamada confirms KedRAB supply is sufficient as the CDC reports rising U.S. (globenewswire.com)
- globenewswire.com (globenewswire.com)
This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.
More coverage in Health Care
- Sector Outlook · 29 September 2026Health Care Distributors Sector Outlook — September 2026
- M&A Update · 29 September 2026Health Care Equipment and Supplies M&A update, 14–28 September 2026
- Sector Outlook · 29 September 2026Health Care Equipment and Supplies Sector Outlook — September 2026
- M&A Update · 29 September 2026Health Care Workforce Services M&A update, 14–28 September 2026
Want this analysis for a company in Health Care Distributors?
Company valuation reports run the same method against a single business — public or private.
